# Novo Nordisk expands collaboration with Valo Health for diabetes and obesity therapies



Novo Nordisk has announced an expansion of its collaboration with Valo Health, aimed at advancing new therapies for type 2 diabetes, obesity, and cardiometabolic diseases through the application of artificial intelligence (AI) and extensive human health datasets. The partnership, which originally centred on cardiovascular disease, now encompasses a total of 20 drug programmes, marking a significant increase from the previously planned 11.

As part of the agreement, Valo Health stands to receive a substantial financial package, which includes an upfront payment, equity investment, and potential milestone payments, potentially totalling $190 million. This financial arrangement highlights the confidence both organisations have in the successful outcome of their joint efforts.

Marcus Schindler, executive vice-president and chief scientific officer at Novo Nordisk, expressed satisfaction with the progress made in the first year of collaboration, stating, “We are very pleased with the progress we have made together with Valo during the first year of our collaboration, and we are excited to expand the scope to put a stronger focus on obesity and type 2 diabetes in addition to cardiovascular disease.” He further underscored the potential benefits of combining Valo Health's capabilities with those of Novo Nordisk, affirming the belief that the partnership will facilitate the advancement of multiple AI-powered, human-centric programmes, ultimately enhancing Novo Nordisk's efforts to increase the number of new drug programmes entering clinical settings.

Utilising Valo Health’s Opal computational platform, the partnership plans to leverage insights drawn from human genetic and longitudinal patient data. This approach aims to focus on the interconnectedness of type 2 diabetes, obesity, and cardiovascular disease, seeking to identify new targets that may lead to innovative drug therapies.

In addition, Novo Nordisk’s alliance with Valo marks a continuation of its strategy to invest in advanced technologies for drug discovery and development. Prior to this collaboration, Novo Nordisk engaged with Variant Bio to concentrate on identifying new therapeutic targets for metabolic conditions. The firm is positioning itself at the forefront of AI integration in pharmaceutical development, seeking to streamline research processes and improve therapeutic outcomes across a range of health challenges.

This strategic collaboration is set to drive growth and innovation in the pharmaceutical industry as it harnesses the power of AI and extensive health data to address critical health issues affecting millions globally.

Source: [Noah Wire Services](https://www.noahwire.com)

## References

* <https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915085> - Corroborates the expansion of the collaboration between Novo Nordisk and Valo Health, including the focus on type 2 diabetes, obesity, and cardiometabolic diseases, and the financial package for Valo Health.
* <https://www.biopharmatrend.com/post/1096-novo-nordisk-and-valo-health-expand-ai-collaboration-for-cardiometabolic-drug-discovery/> - Supports the details of the expanded collaboration, including the increase from 11 to 20 drug programs and the financial terms such as upfront and milestone payments.
* <https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915085> - Quotes from Marcus Schindler, executive vice-president and chief scientific officer at Novo Nordisk, regarding the progress and future focus of the collaboration.
* <https://www.biopharmatrend.com/post/1096-novo-nordisk-and-valo-health-expand-ai-collaboration-for-cardiometabolic-drug-discovery/> - Details the use of Valo Health’s Opal computational platform and the focus on human genetic and longitudinal patient data to identify new therapeutic targets.
* <https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915085> - Explains the strategic importance of the collaboration in advancing AI-powered, human-centric drug discovery programs and Novo Nordisk’s strategy to increase new drug programs in clinical settings.
* <https://www.biopharmatrend.com/post/1096-novo-nordisk-and-valo-health-expand-ai-collaboration-for-cardiometabolic-drug-discovery/> - Highlights Novo Nordisk’s broader strategy in investing in advanced technologies for drug discovery and development, including previous collaborations like the one with Variant Bio.
* <https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915085> - Provides context on the initial collaboration between Novo Nordisk and Valo Health, which started in 2023 and focused on cardiovascular disease.
* <https://www.biopharmatrend.com/post/1096-novo-nordisk-and-valo-health-expand-ai-collaboration-for-cardiometabolic-drug-discovery/> - Mentions the Phase 2 trial setback for Valo in diabetic retinopathy and how the expanded collaboration aligns with Novo Nordisk’s core areas of focus.
* <https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915085> - Details the financial terms, including the upfront payment, equity investment, and potential milestone payments totaling $190 million and up to $4.6 billion.
* <https://www.biopharmatrend.com/post/1096-novo-nordisk-and-valo-health-expand-ai-collaboration-for-cardiometabolic-drug-discovery/> - Explains the role of AI and human-centric models in the collaboration, focusing on identifying novel therapeutic targets and developing new drug therapies.